Vnitřní lékařství 8/2020

ORIGINAL ARTICLE The role of metabolic syndrome in the induction of chronic pancreatitis after a first attack of acute pancreatitis – multicenter trial E16 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(8): e12–e16 /  www.casopisvnitrnilekarstvi.cz syndrome is a possible factor in the faster progression of the changes from an acute to a chronic pancreatic form. We are aware the evaluated set and its results can be influenced by the errors of small numbers, due to this fact the described findings have a certain limitation and further studies with a bigger set is needed to confirm the findings in this article. Conclusion 1) In the development of chronic pancreatitis, in accordance with the mechanistic definition of chronic pancreatitis, acute pancreatitis is an etiological factor, not only in the form of acutely recurrent acute pancreatitis but even after one, clinically relevant acute pancreatitis. 2) We have shown that there is no fundamental difference between the etiology of acute pancreatitis and the development of chronic pancreatitis. 3) In some patients with chronic pancreatitis after acute pancre‑ atitis, metabolic syndrome is present. We believe that the presence of metabolic syndrome may accelerate the development of chronic pancreatitis after acute pancreatitis. Disclosure Statement The authors declare that they have nothing to disclose. Funding Sources No grants or financial support were provided. REFERENCES 1. Albertin KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on epidemiology and Prevention, National Heart, Lung and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Associa‑ tion for the Study of Obesity. Circulation 2009; 120(16): 1640–1605 2. Singh RG, Yoon HD, Wu LM, et al. Ectopic fat accumulation in the pancreas and its clinical relevance: A systemic review, meta‑analysis andmeta‑regression. Metabolism2017; 69: 1–18. 3. Catanzaro R, Cuffari B, Italia A, et al. Exploring the metabolic syndrome: Nonalcoholic fatty pancreas disease. World J Gastroenterol 2016; 14: 22(34): 7660–7675. 4. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. Anthropometric measures, body mass index and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Con‑ sortium (PanScan). Arch Intern Med 2010; 170: 791–802. 5. Aune D, Greenwood DC, Chan DS, et al. Body mass index abdominal fatness and pan‑ creatic cancer risk: a systematic review and non‑linear dose‑response meta‑analysis of prospective studies. Ann Oncol 2012; 23: 843–852. 6. Etemad B, Whitcom DC. Chronic pancreatitis: diagnosis, classification and new genetic developments. Gastroenterology 2001; 120(3): 682–707. 7. Ammann RW, Muellhaupt B. Progression of alcoholic acute pancreatitis to chronic pan‑ creatitis. Gut 1994; 35(4): 552–556. 8. Pelli H, Lappalainen‑Neto R, Piironen A, et al. Risk factors for recurrent acute – alcohol associated pancreatitis: a prospective analysis. Scand J Gastroenterol 2008; 43(5): 614–621 9. Kloeppel G, Maillet B. The morphological basis for the evolution of acute pancreatitis into chronic pancreatitis. Virchows Archiv A Pathol Anatomy 1992; 420(1): 1–4. 10. Whitcomb D, Frulloni L, Garg P, et al. Chronic pancreatitis: An international draft con‑ sensus proposal a new mechanistic definition. Pancreatology 2016; 16: 218–224. 12. Nojgaard C, Becker U, Matzen P, et al. Progression from acute to chronic pancreatitis: prognostic factors, mortality and natural course. Pancreas 2011, 40(8); 1195–1200. 13. Takeyama Y. Long term prognosis of acute pancreatitis in Japan. Clin Gastroenterol Hepatol 2009; 7 (11): 515–517. 14. Löhr JM, Dominguez‑Munoz E, Rosendahl J, et al. United European Gastroenterology evidence‑based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPa‑ nEU). United European Gastroenterol J. 2017; 5(2): 153–199. doi:10.1177/2050640616684695 15. Gullo L, Priori P, Labo G. Natural history of acute pancreatitis and its relationship to chronic pancreatitis. In Bianchi Porro G, Banks PA. Acute pancreatitis. Advances in patho‑ genesis, diagnosis and treatment. Masson: Milano 1984: 87–93, ISBN 978-8821416590. 16. Yadav D, O’Connell M, Papachristou GI. Natural history following the first attack of acu‑ te pancreatitis. Amer J Gastroenterol 2012; 107(7): 1096–1103. 17. Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat Rev Gas‑ troenterol Hepatol 2010; 7(3): 131–145. 18. Nordback I, Pelli H, Lappalainen‑Lehto R, et al. The recurrence of acute‑alcohol asso‑ ciated pancreatitis can be reduced: randomized controlled trial. Gastroenterology 2009; 136(3): 848–855. 19. Sandzen B, Rosenmuller M, Haapamaki MM, et al. First attack of acute pancre‑ atitis in Sweden 1988-2003: incidence, aetiological classification, procedures and mortality - a register study. BMC Gastroenterology 2009; 9: 18. DOI: http//dx.doi.org /10.1186/1471-230X-9-18. 20. Berlinsson S, Sward P, Kalaitzakis E. Factors that affect disease progression after first attack of acute pancreatitis. Clin Gastroenterol Hepatol 2015; 13: 1662–1669. 21. Sankaran SJ, Xiao AY, Wu LA, et al. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta‑analysis. Gastroenterology 2015; 149(6): 1490–1500. e1., doi: 101053/j.gastro.2015. 07. 066. 22. Ali UA, Issa Y, Hagenaars J, et al. Risk of recurrent pancreatitis and progression to chro‑ nic pancreatitis after a first episode of acute pancreatitis. Clin Gastroenterol 2016; 14(5): 738–746. doi: 1.1016/j.cgh.2015. 12. 040. 23. Burgerhart JS, van de Meeberg PC, Siersema PD, et al. Nocturnal and daytime esoph‑ ageal acid exposure in normal‑weight, overweight, and obese patients with reflux symp‑ toms. Eur J Gastroenterol Hepatol 2014; 26(1): 6–10. 24. Ryan AM, Healy LA, Power DG, et al. Barrett esophagus: prevalence of central adi‑ posity, metabolic syndrome and a proinflammatory state. Ann Surg 2008; 247: 909–915. 25. Roselli M, Lotersztajn S, Vizutti F, et al. The metabolic syndrome and chronic liver di‑ sease. Curr Pharm Des 2013; 20(31): 5010–5024. 26. Polyzos SA, Kountouras J, Mantzoros CS. The role of adiponectin in nonalcoholic fatty liver disease. Metabolism 2016; 65(8): 1062–1079. 27. Adrych K, Smoczynski M, Stelmanska E, et al. Serum adiponectin and leptin concent‑ ration in patients with chronic pancreatitis of alcoholic and nonalcoholic origin. Pancre‑ as 2008; 36(2): 120–124. 28. Van‑Chen Wu, Chih‑Yuan Wag. Association between non‑alcoholic fatty pancreatic disease and the metabolic syndrome. Case‑control retrospective study. Cardiovasc Dia‑ betol 2013; 12: 77, doi: 10.1186/1475-2840-12-77. 29. Khatua B, El‑Kurdi B, Singh VP. Obesity and pancreatitis. Curr Opinion Gastroenterol 2017; 33(5): 374–382. 30. Tariq H, Nayudu S, Akella S, et al. Non‑alcoholic fatty pancreatic disease: A review of literature. Gastroenterol Res 2016; 9(6): 87–91. 31. Melitas C, Meiselman M. Metabolic pancreatitis: Pancreatic steatosis, hypertriglyceri‑ demia, and associated chronic pancreatitis in 3 patients with metabolic syndrome. Case Rep Gastroenterol 2018; 12: 331–336. 32. Babinets KS, Melnyk NA, Shevchenko NO, et al. Complex therapy of chronic pancrea‑ titis with metabolic syndrome. Wiad Lek 2018; 13(2): 1–12.